IQVIA and Veeva Extend Clinical Trial Partnership
The companies expand their collaboration to standardize clinical trial software across global development studies.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust that the increasing use of AI in clinical trials is safe for patients?
IQVIA has adopted a suite of Veeva clinical trial software as its enterprise standard to unify its global development operations. The partnership extension aims to simplify and connect clinical trials through integrated technology.
Why it matters
The deal addresses the industry-wide need to streamline complex clinical processes and integrate artificial intelligence into drug development. By standardizing software, companies hope to reduce friction for sponsors and research organizations.
IQVIA now utilizes Veeva eTMF, CTMS, Study Startup, and Site Connect as its enterprise standard applications. Veeva Study Builder technology enables the configuration of clinical systems in as little as one day.
The players
IQVIA
This is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
Veeva
The company is a leading provider of cloud-based software solutions for the global life sciences industry.
The details
IQVIA will implement the Veeva clinical technology stack across its portfolio of global development studies to improve data connectivity. This integration follows Veeva's recent investment in artificial intelligence to meet growing demand from drug developers and services firms.
Timeline
IQVIA and Veeva first partnered in 2025.
Data regarding clinical trial AI usage was published in September 2026.
The partnership extension was finalized in October 2026.
The Tech Race
The adoption of Veeva Study Builder represents a major shift toward automated system configuration in the clinical research sector. This move intensifies the ongoing race to replace legacy, manual data systems with agile, cloud-based software stacks that reduce study setup times.
For users and developers at clinical research sites, this standardization offers a more consistent interface and workflow across different study platforms. By reducing system configuration time to one day, the technology allows teams to deploy new trials and data tools more rapidly.
The takeaway
Companies are increasingly prioritizing software integration to handle the complexity of modern clinical development. Standardizing on unified technology platforms is becoming a baseline requirement for major research organizations to maintain operational speed.
Further reading
Learn more about the latest innovations in clinical research at Biotech.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you trust that the increasing use of AI in clinical trials is safe for patients?
